Organisation paid for research Program year 2025 Source: CMS Open Payments

Dharma

Neither a doctor nor a teaching hospital

Research payments

$200,987

62 payments

Through program year 2025, Dharma is reported as receiving $200,987 in research payments, across 62 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $12,595 7
2024 Research $36,694 9
2023 Research $48,073 16
2022 Research $78,207 22
2021 Research $20,151 5
2020 Research $5,268 3

Breakdown

Who paid Research payments · program years 2020–2025
  1. GlaxoSmithKline, LLC. $200,987 62 payments
Studies the money was for Research payments · program years 2020–2025
  1. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $142,174 42 payments
  2. A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $25,074 6 payments
  3. A Multinational, Single Arm, Observational Study to Evaluate the Real- $23,247 12 payments
  4. A Phase II, Observer-Blind, Randomized, Controlled Study to Evaluate T $8,991 1 payment
  5. Post-Authorisation Safety (Pas) Observational Cohort Study to Quantify $1,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record